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Paclitaxel poliglumex (PPX), a macromolecule drug conjugate linking paclitaxel to polyglutamic acid, reduces systemic exposure to
peak concentrations of free paclitaxel. Patients with non-small-cell lung cancer (NSCLC) who had received one prior platinum-based
chemotherapy received 175 or 210mgm
 2 PPX or 75mgm
 2 docetaxel. The study enrolled 849 previously treated NSCLC
patients with advanced disease. Median survival (6.9 months in both arms, hazard ratio¼1.09, P¼0.257), 1-year survival
(PPX¼25%, docetaxel¼29%, P¼0.134), and time to progression (PPX¼2 months, docetaxel¼2.6 months, P¼0.075) were
similar between treatment arms. Paclitaxel poliglumex was associated with significantly less grade 3 or 4 neutropenia (Po0.001) and
febrile neutropenia (P¼0.006). Grade 3 or 4 neuropathy (Po0.001) was more common in the PPX arm. Patients receiving PPX had
less alopecia and did not receive routine premedications. More patients discontinued due to adverse events in the PPX arm
compared to the docetaxel arm (34 vs 16%, Po0.001). Paclitaxel poliglumex and docetaxel produced similar survival results but had
different toxicity profiles. Compared with docetaxel, PPX had less febrile neutropenia and less alopecia, shorter infusion times, and
elimination of routine use of medications to prevent hypersensitivity reactions. Paclitaxel poliglumex at a dose of 210mgm
 2 resulted
in increased neurotoxicity compared with docetaxel.
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Lung cancer is the most common cancer and one of the most lethal
cancers. In the United States, an estimated 213380 new lung cancer
cases and 160390 lung cancer deaths were expected in 2007 (Jemal
et al, 2007). For patients who present with advanced-stage disease
(IIIb or IV), platinum-based multi-agent chemotherapy modestly
improves survival compared with best supportive care or single-
agent therapy (Pfister et al, 2004). However, nearly all patients
relapse, and only 10–20% survive 2 years. Three agents are
currently approved for second-line therapy in advanced non-
small-cell lung cancer (NSCLC). Docetaxel and erlotinib were
approved on the basis of improved survival compared with best
supportive care (Shepherd et al, 2000, 2005). Pemetrexed received
approval as second-line therapy due to its similarity in survival
and response rates with lower toxicity than that of docetaxel,
although statistical noninferiority was not achieved (Hanna et al,
2004). Despite response rates of approximately 10%, second-line
treatment improves survival by approximately 2 months compared
with best supportive care.
Owing to the palliative nature of second-line therapy in NSCLC
and its relatively modest effect on survival, minimising the toxicity
of therapy is an important consideration. Additional effective
therapies that achieve that goal are needed.
Paclitaxel poliglumex (PPX) is a macromolecular polymer–drug
conjugate that links paclitaxel to a biodegradable polymeric
backbone consisting of L-glutamic acid residues. Because the
conjugation site is through the 20 hydroxyl of paclitaxel, a site
crucial for tubulin binding, conjugated paclitaxel does not interact
with b-tubulin and is biologically inactive (Singer et al, 2005).
Paclitaxel poliglumex is relatively stable in circulation; the area
under the curve (AUC) of unconjugated paclitaxel is 1–2% of the
AUC of conjugated paclitaxel. Clinical plasma pharmacokinetics of
PPX show a biphasic decline with a prolonged distribution phase
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sand an elimination phase with a long terminal half-life (Bernareggi
et al, 2005). The total systemic exposure to unconjugated paclitaxel
is similar after administration of equivalent doses of PPX and
standard paclitaxel; however, the Cmax values for paclitaxel are
significantly lower in patients treated with PPX. (Bernareggi et al,
2005). The single-cycle, maximum tolerated dose of PPX in phase
Ia study was 233mgm
 2 every 3 weeks, with neutropenia being the
dose-limiting toxicity (Boddy et al, 2005). In the phase Ib portion
of the trial, in which CT-2103 was administered every 2 weeks, the
maximum tolerated dose was 177mgm
 2, with neuropathy being
the dose-limiting side effect. Neither study was able to address
multi-cycle toxicities. A dose of 210mgm
 2 was chosen for the
current study in view of the expectation that most patients will
have had prior paclitaxel therapy and a potential for cumulative
neuropathy with prolonged administration of CT-2103.
Macromolecules such as PPX passively accumulate in tumour
tissues by taking advantage of the hyperpermeable tumour
vasculature and reduced lymphatic clearance. This phenomenon
is known as the enhanced permeation and retention (EPR) effect,
which results in a 10- to 100-fold increase in intratumoral drug
concentrations when compared with an equivalent dose of the
drug given conventionally (Matsumura and Maeda, 1986; Greish
et al, 2003). To take advantage of the EPR effect, macromolecules
have to remain in circulation for at least 6h (Matsumura and
Maeda, 1986). The prolonged circulation time of PPX facilitates
tumour accumulation through the EPR effect, as has been
demonstrated in animal models (Li et al, 2000). The release of
paclitaxel from the polymeric backbone is dependent on lysosomal
proteases, particularly cathepsin B (Shaffer et al, 2007). In
malignant tumours and premalignant lesions, increased cathepsin
B mRNA expression is associated with elevated cathepsin B protein
levels and activity and correlates with tumour invasion (Podgorski
and Sloane, 2003).
In a phase II trial of 28 patients who were either elderly, had
performance status (PS) 2, or both with treatment-naı ¨ve advanced
NSCLC, PPX at a dose of 175mgm
 2 every 3 weeks yielded a
median survival of 8.1 months in a PS 0–1 population and 5.4
months in a PS 2 cohort (Richards et al, 2005). This dose was well
tolerated with a median of three cycles administered. The disease
control rate was 71% (2 partial remissions and 15 patients with
stable disease).
Given the enhanced efficacy of PPX in preclinical models, its
activity in phase II, and its tolerability, the present trial was
initiated to compare survival in NSCLC patients treated with PPX
to that of docetaxel as second-line therapy in patients who had
previously received a platinate combination.
MATERIALS AND METHODS
The study was approved by the local research ethics committees.
All patients gave written informed consent.
Study design
STELLAR 2 was an open-label, phase III study comparing
docetaxel with PPX. Paclitaxel poliglumex was administered as a
10- to 20-min infusion at 210mgm
 2 for advanced disease NSCLC
patients with Eastern Cooperative Oncology Group PS 0 or 1 and at
175mgm
 2 for patients with PS 2. The dose was reduced for PS 2
patients after the trial had started based on the results from an
ongoing study in PS 2 patients. In that study, the data monitoring
committee noted an increased incidence of death resulting from
neutropenia in 96 patients treated with 235mgm
 2 PPX. As a
result of these observations, the dose was reduced to 175mgm
 2
PPX (O’Brien et al, in press). Docetaxel was administered as a 1-h
intravenous (i.v.) infusion at 75mgm
 2. In both study arms,
patients received i.v. treatment every 3 weeks. Patients in the
docetaxel arm received routine hypersensitivity reaction (HSR)
prophylaxis including corticosteroids (e.g. dexamethasone 20mg
i.v.), histamine 2 receptor blockers (e.g. cimetidine 300mg i.v.),
and antihistamines (e.g. diphenhydramine 50mg i.v.). These
agents were administered just before chemotherapy. Patients in
the PPX arm received no standard HSR prophylaxis. Patients were
treated until disease progression, intolerable toxicity, patient
withdrawal of consent, or investigator decision to stop treatment.
All concurrent medications were recorded. Anti-emetic prophy-
laxis was permitted. Granulocyte colony-stimulating factor
(G-CSF) and granulocyte–macrophage colony-stimulating factor
were administered according to American Society of Clinical
Oncology guidelines.
Patients were stratified based on stage (IV vs other), PS (0 or 1 vs
2), start of front-line (platinum-based) chemotherapy (o16 weeks
from randomisation vs X16 weeks from randomisation), gender,
and prior taxane therapy (yes vs no).
End points
The primary end point of this study was the comparison of overall
survival of patients treated with PPX to that of docetaxel. No
patients were censored regardless of the apparent cause of death.
Secondary objectives included response rate, time to progression
(TTP), safety, and quality of life. Response status was established
by response evaluation criteria in solid tumours (RECIST)
(Therasse et al, 2000). Computed tomography (CT) or other
imaging techniques were used to assess patients during the third
week of every other cycle. For patients who completed therapy and
had no evidence of disease progression, re-evaluation of indicator
lesions was obtained every 8 weeks until documentation of disease
progression or alternative therapy.
Safety data were collected on all patients. In addition, disease-
related symptoms were measured by the functional assessment of
cancer therapy-lung cancer symptom (FACT-LCS) scale at baseline
and within 3 days of each treatment administration.
Eligibility
All patients enrolled in this study had histologically or cytologi-
cally confirmed advanced NSCLC and had been treated with a
single platinum-based systemic therapy. Patients who received
radiation sensitising doses of platinum-based chemotherapy with
concurrent chest radiation were not eligible. Patients who received
full doses of adjuvant chemotherapy were eligible. Patients were
X18 years with adequate end organ indices, including baseline
absolute neutrophil count (ANC) X1500ml
 1, platelet count
X100000ml
 1, adequate renal function defined as creatinine
p1.5 times the upper limit of normal, bilirubin 41.0 times the
upper limit of normal, transaminases p2.5 times the upper limit of
normal (p5 times the upper limit if hepatic metastases were
documented), and alkaline phosphatase p2.5 times the upper limit
(unless documented bone metastases were present). Patients with
known brain metastases were required to have stable disease after
standard antitumour treatment (e.g. whole brain radiation,
stereotactic radiation, or surgical resection) and be either off
corticosteroid treatment or on tapering doses. Those who had
undergone surgery had to be fully recovered. Patients with
reproductive potential were required to commit to adequate
contraception.
Exclusion criteria included evidence of small cell, carcinoid, or
mixed small cell/NSCLC histologies; no previous treatment with a
platinum regimen for NSCLC; other concurrent, active primary
malignancies requiring treatment with the exception of carcinoma
in situ of the uterine cervix or nonmelanomatous skin cancer;
baseline grade X2 neuropathy; clinically significant infection;
exposure to other investigational agents within 4 weeks of
study entry; unstable medical conditions, including myocardial
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sinfarction within the prior 6 months, inadequately treated chronic
obstructive pulmonary disease, or significant arrhythmias. All
patients were required to sign informed consents.
Criteria for removal from study
Patients were treated until documentation of disease progression
clinically or on CT imaging or in the event of intolerable toxicities,
including persistent grade X3 nonhaematologic toxicities, grade 4
HSR, grade 3 HSR despite adequate prophylaxis, or other toxicities
precluding study continuation. Other criteria for treatment
discontinuation included withdrawal of consent, individual
physician discretion for reasons unrelated to toxicities, and
violation of study protocol, including patient noncompliance.
Dosing and dose modifications
The doses of study agents were reduced for the following
conditions: (1) febrile neutropenia at any time; (2) grade 4
neutropenia lasting 47 days; (3) failure to recover to ANC of
1500ml
 1 by day 22; (4) platelet count 420000 or o50000 with
associated bleeding; (5) grade X2 neuropathy; (6) any other
attributable grade 3 or 4 nonhaematologic toxicity, with the
exception of manageable nausea and vomiting or HSR; and
(7) dose delays due to drug-related toxicity.
For PPX, the first onset of dose-limiting toxicity mandated a
dose reduction to 175mgm
 2 for patients whose initial dose was
210 and to 135mgm
 2 for initial doses of 175mgm
 2; second dose
reductions mandated a decrease to 135 or 90mgm
 2, respectively.
Once a dose reduction was instituted, doses were not re-escalated.
Patients who experienced grade p3 HSR during or following
treatment were allowed to continue treatment at investigator’s
discretion, but were required to receive standard premedication in
accordance with institutional guidelines.
For docetaxel, the first onset of dose-limiting toxicity mandated
a dose reduction to 75mgm
 2; second dose reductions mandated a
decrease to 55mgm
 2. Once a dose reduction was instituted, doses
were not re-escalated. Patients who experienced grade p3 HSR
during or following treatment were allowed to continue treatment
at investigator’s discretion, but were required to receive standard
premedication in accordance with institutional guidelines.
Efficacy parameters and statistical considerations
Overall survival was defined as the interval between randomisation
and death from any cause. Patients remaining alive, including
those lost to follow-up, were censored at the date of last contact.
Nonstratified log rank testing was used for the formal primary
comparison of survival. This study targeted accrual of 840
evaluable patients, which guaranteed 80% power and 0.05 type I
error to show a 1.5-month improvement (30% increase) in median
survival from baseline of 6 to 7.5 months. The study was slated to
accrue over 18 months with an additional 6 months of follow-up. A
secondary, noninferiority analysis of overall survival was also
performed using the fraction retention method described by
Rothmann et al (2003). In addition, secondary analyses comparing
each treatment arm were conducted using Cox regression models,
which included covariates that reflected prognostic factors
associated with survival in patients with NSCLC.
Response was assessed according to RECIST criteria. Disease
control was determined by the percentage of patients alive without
disease progression for at least 12 weeks. All randomised patients
were included in these comparisons using Fisher’s exact test.
Time to progression was defined as the time interval between
randomisation and the first observation of disease progression due
to any cause. Primary analysis of TTP was made using an
unstratified log rank test. Secondary analyses of TTP were
performed using Cox regression models with covariates used in
the secondary analysis of survival.
Safety variables were summarised by descriptive statistics for
patients who received any study treatment. All toxicities were
graded according to the National Cancer Institutes Common
Toxicity Criteria, version 2. Toxicities were compared between the
treatment arms using Fisher’s exact test.
Quality of life
Disease-related symptoms were measured by the FACT-LCS scale,
a validated, 5-point Likert-type scale ranging from 0 (not at all) to
4 (very much). The total LCS score ranged from 0 to 28, with
higher scores indicative of fewer symptoms. Fisher’s exact test for
equal proportion of patients achieving at least a 2-point increase in
FACT-LCS score from baseline to week 3 was performed in the
overall sample and by each baseline covariate strata. Patients with
a missing FACT-LCS score at week 3 were classified as having a
o2-point increase in the primary analysis data, but classified as
missing and excluded from the supplemental analysis.
RESULTS
Disposition of patients
A total of 849 patients were randomised to receive either PPX
(n¼427) or docetaxel (n¼422). Five patients (two patients had
progressive disease, one patient requested withdrawal, one patient
did not comply with the protocol, and no reason was given for one
patient) in the PPX treatment arm and six patients (one patient
died of pulmonary embolism before receiving study drug, two
patients had progressive disease, one patient requested withdrawal,
the physician requested withdrawal not related to toxicity for one
patient, and one patient did not comply with the protocol) in the
docetaxel arm were randomised but did not receive study drug.
The first patient was randomised on 18 October 2002 and the last
patient was enrolled on 13 August 2004.
Demographic breakdown is included in Table 1. Both arms were
well balanced with regard to baseline characteristics: 72% of
patients were male, 92% were Caucasian, 81% had stage IV disease,
and 29% of patients had received prior taxanes. The median age
was 61 years in the PPX arm and 62 in the docetaxel arm. The
majority of patients (57%) came from western Europe and Canada;
34% came from the United States.
The most frequent reasons for stopping treatment were
progressive disease (57% in the PPX arm compared with 63% in
the docetaxel arm, P¼0.107) and adverse events (34% in the PPX
arm compared with 16% in the docetaxel arm, Po0.001).
Additionally, 4% of patients in the PPX arm withdrew consent
compared with 8% in the docetaxel arm (P¼0.011).
Efficacy summary Median overall survival was 6.9 months in
both arms of the study (P¼0.26) (Table 3). One-year survival rates
were 25% in the PPX arm and 29% in the docetaxel arm
(P¼0.134). The 2-year survival rates were higher in the docetaxel
arm (12 compared with the PPX arm (9%)). These differences were
not statistically significant (P¼0.195). Survival curves are shown
in Figure 1.
Noninferiority, defined as retention of X90% of docetaxel effect,
was not observed between the two arms (hazard ratio (HR)¼1.09;
95% confidence interval (CI)¼0.94–1.27). In subsequent
analyses, a method that uses historic effect size estimates of
placebo-controlled trials to adjust the HR observed when working
with a nonplacebo control was implemented. The results from
this method yielded an HR of 0.61 (95% CI¼0.38, 0.98), indicating
that PPX is an active agent when indirectly compared with
placebo.
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sResponse and progression data
The overall response rate for the PPX arm was 8%, with no
complete responses (CRs) (Table 3). The overall response rate for
the docetaxel arm was 12%, with two CRs. Disease control, defined
as absence of progression during the first 12 weeks, occurred in
40% in the PPX arm compared with 45% in the docetaxel arm.
There was no significant difference in median TTP: 2.0 months
in the PPX arm compared with 2.6 months in the docetaxel arm
(HR¼1.13; log rank P¼0.075). Time to progression curves are
shown in Figure 2. There was no difference in subsequent
therapies: 11% of those enrolled in the PPX arm went on to
radiation therapy compared with 13% in the docetaxel arm. In
both arms, 57% received additional chemotherapy, but no specific
agents predominated.
Quality of life
The primary FACT-LCS analysis consisted of 767 patients (PPX:
n¼379; docetaxel: n¼388). There was no difference between the
two treatment groups in the proportion of subjects achieving at
least a 2-point increase in FACT-LCS score from baseline to cycle 3
(P¼0.329). Both treatment groups reported similar proportions of
FACT-LCS scale score and item score changes from baseline over
time. During the study period, 41% of patients treated with
docetaxel achieved at least a 2-point improvement in FACT-LCS
score from baseline compared with 34% of patients treated with
PPX.
Toxicity profile
Drug delivery The median number of cycles received was two in
the PPX arm and three in the docetaxel arm. More patients
received X6 cycles in the docetaxel arm (Po0.001). In aggregate,
patients received 490% of mean expected dose during the second
and subsequent cycles.
Relative toxicities
Patients enrolled in the docetaxel arm were significantly more
likely to experience grade 3 or 4 neutropenia (37 vs 14%, Po0.001)
and febrile neutropenia (6 vs 2%, P¼0.006) (Table 2). Alopecia
also occurred more frequently in the docetaxel arm (43 vs 14%,
Po0.001). Patients enrolled in the PPX arm were significantly
more likely to experience grade 3 or 4 HSR (3 vs o1%, P¼0.007)
and neuropathy (19 vs 3%, Po0.001). Neuropathy of all grades
occurred in 50% of patients in the PPX arm and 30% of patients in
the docetaxel arm. Severe neuropathy (common toxicity criteria
grade 3 or 4) was observed in 19% of patients in the PPX arm and
3% of patients in the docetaxel arm. Of note, only grade 3 events
were seen in the docetaxel arm. There was a general trend towards
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Figure 1 Kaplan–Meier plot of overall survival (intent-to-treat data set).
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Figure 2 Kaplan–Meier plot of time to disease progression (intent-to-
treat data set). HR, hazard ratio; PPX, paclitaxel poliglumex.
Table 1 Demographic and baseline characteristics
PPX (n¼427) Docetaxel (n¼422)
Gender
Male 308 (72.1%) 302 (71.6%)
Female 119 (27.9%) 120 (28.4%)
Race
Caucasian 397 (93.0%) 381 (90.3%)
Black 19 (4.4%) 21 (5.0%)
Asian 5 (1.2%) 5 (1.2%)
Hispanic 4 (0.9%) 11 (2.6%)
Other 1 (0.2%) 4 (0.9%)
Unknown 1 ( 0.2%) 0 ( 0%)
Age at randomisation
N 427 422
Mean (s.d.) 61.3 (9.81) 62.1 (9.72)
Median (range) 62.0 (30–87) 63.0 (34–85)
Geographic location
United States 150 (35.1%) 140 (33.2%)
Western Europe and Canada 240 (56.2%) 245 (58.1%)
Other 37 (8.7%) 37 (8.8%)
ECOG performance rating
0 93 (22%) 80 (19%)
1 277 (65%) 280 (66%)
2 57 (13%) 62 (15%)
Disease stage
IV 342 (80%) 343 (81%)
Other 84 (20%) 75 (18%)
Unknown 1 (o1%) 4 (o1%)
Time since start of first-line chemotherapy
o16 weeks 132 (31%) 133 (32%)
X16 weeks 295 (69%) 289 (68%)
Prior taxane use
Yes 127 (30%) 123 (29%)
No 286 (67%) 287 (68%)
Unknown 14 (3%) 12 (3%)
ECOG¼Eastern Cooperative Oncology Group; PPX¼paclitaxel poliglumex.
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san increasing incidence of severe neuropathy by cycle in the PPX
arm through cycle 4. The mean cumulative dose of PPX at the first
event of neuropathy was 532.9mgm
 2. A similar pattern was not
observed in the docetaxel arm.
The incidence of febrile neutropenia was 2% in the PPX arm
compared with 6% in the docetaxel arm (P¼0.002). The use of
supportive care, including transfusions, erythropoietin, and
G-CSF, was lower in the PPX treatment arm. Grade 3 or 4
infections occurred more frequently in the docetaxel arm (11%)
than in the PPX arm (7%).
Twelve per cent of patients in the PPX arm and 16% of patients
in the docetaxel arm died within 30 days of treatment, but only 2%
of these deaths were attributable to study drugs, 9% appeared to be
disease related, and 3% were due to comorbidities.
The incidence of HSR was 5% for the PPX arm, without routine
HSR prophylaxis, compared with 3% for the docetaxel arm, with
HSR prophylaxis.
DISCUSSION
Paclitaxel poliglumex and docetaxel produced similar results for
TTP and overall survival in one of the largest phase III studies to
date evaluating second-line chemotherapy in NSCLC. The TTP and
survival results in the current trial are similar to results reported
for docetaxel, pemetrexed, and erlotinib observed in smaller
randomised studies (Fossella et al, 2000; Shepherd et al, 2000;
Hanna et al, 2004) (Table 3). Collectively, these data suggest that
second-line therapy with an active agent has a modest survival
advantage over supportive care alone and that the effects of
docetaxel, PPX, pemetrexed, and erlotinib are similar.
Patients treated with PPX received a median of two cycles of
therapy vs three cycles in the docetaxel arm with more patients
withdrawing from PPX for adverse events and more patients in the
docetaxel arm withdrawing for progressive disease. The dose of
210mgm
 2 PPX used in this study may have been higher than
optimal and may have been responsible for the relatively high
withdrawal rate. Nevertheless, patients treated with PPX had
significantly less neutropenia and febrile neutropenia and required
less growth factor and transfusion support. However, they did
experience more grade 3 neuropathy (19 vs 3%), a common cause
for discontinuation. A general trend towards increasing incidence
by cycle was seen in the PPX arm. Additional experience in
patients with other diseases suggests that the optimal dose for
repeated cycles of PPX is 175mgm
 2 with early dose reduction for
development of even grade 1 neuropathy. In this study, the dose
was reduced only when persistent grade 2 neuropathy had
developed. Studies with paclitaxel have consistently failed to
demonstrate a dose–response relationship. In contrast, in a phase
III study of single-agent PPX at 175mgm
 2, grade 3 neuropathy
occurred in 4% of patients despite administration of a median of
four cycles of therapy (O’Brien et al, in press). In that study in PS 2
patients, PPX was not inferior to single-agent therapy with either
gemcitabine or vinorelbine (median survival¼220 vs 198 days,
respectively; HR¼0.95) and produced fewer grade 3 or 4 toxicities.
Paclitaxel poliglumex has advantages over docetaxel in ease of
administration, requiring a 10- to 20-min peripheral vein infusion
without routine premedications and a low incidence of neutro-
penic fever or infections. An additional advantage is the decreased
rate of alopecia (43 vs 14%) due to reduced systemic exposure to
high levels of free paclitaxel. Despite prior taxane exposure in 30%
of patients treated with PPX, the incidence of HSR was only 5%
(3% grade 3 or 4) compared with 3% (o1% grade 3 or 4) for
docetaxel.
Preclinical and clinical studies suggest an interaction between
PPX and oestrogen (Ross et al, 2006). A clinical trial in women
with oestradiol levels 430pgml
 1 is being conducted to test the
hypothesis that women with normal oestradiol levels who are
treated with PPX and carboplatin will have improved survival
compared to women treated with paclitaxel and carboplatin.
Final conclusions
Paclitaxel poliglumex produces similar survival to docetaxel as
second-line treatment in NSCLC with less febrile neutropenia and
alopecia and greater ease of administration. The higher incidence
of neuropathy can likely be reduced by lowering the starting dose
to 175mgm
 2 and using early dose reduction for development of
even grade 1 neuropathy. Additional studies in patients under-
going second-line therapy are needed to validate this.
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